CTOs on the Move

RenovoRx

www.renovorx.com

 
RenovoRx is a clinical-stage biopharmaceutical company focused on fighting cancer through the localized treatment of difficult to treat tumors via our proprietary RenovoRx Trans-Arterial Micro-Perfusion (RenovoTAMP®) therapy platform. RenovoTAMP utilizes approved chemotherapeutics with validated mechanisms of action and well-established safety and side effect profiles, with the goal of increasing their efficacy, improving their safety, and widening their therapeutic window. Our lead product candidate, RenovoGem, is a combination of gemcitabine and our patented delivery system regulated by the FDA as a novel oncology drug product to treat unresectable locally advanced pancreatic cancer (LAPC). Targeted therapy via RenovoTAMP platform safely and without ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.renovorx.com
  • 4546 El Camino Real Suite B1
    Los Altos, CA USA 94022
  • Phone: 650.284.4433

Executives

Name Title Contact Details

Similar Companies

Applied Biophysics Inc

Applied Biophysics Inc is a Troy, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Combimatrix Molecular Diagnostics

Combimatrix Molecular Diagnostics is a Irvine, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Icagen

Icagen is a Durham, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Genetics Center

Genetics Center is a Orange, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Arkuda Therapeutics

Arkuda Therapeutics is a biotechnology company applying insights into lysosomal biology to drive the development of medicines to change the trajectory of neurodegenerative disease. Arkuda`s lead program ARKD-104 aims to correct progranulin deficiency and lysosomal dysfunction in patients with GRN-related frontotemporal dementia (FTD-GRN), a genetically-defined subtype of frontotemporal dementia caused by an autosomal dominant mutation in the progranulin (GRN) gene. The company is further exploring the therapeutic potential of its molecules in other neurodegenerative diseases where genetic links to dysfunction in progranulin biology have been established, including Alzheimer`s Disease and Parkinson`s Disease. Arkuda is backed by leading investors including Atlas Venture, Cormorant Asset Management, Pfizer Ventures, funds managed by Tekla Capital Management LLC, Mission BioCapital, and Eli Lilly and Company.